Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.65 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | PPID | Q08752 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4880780 | 0.89 | TRPV1 (0.55) | EPHX2NR1H4TRPV1NPC1CNR1 | |
| SCHEMBL3815572 | 0.83 | EPHX2 (0.67) | EPHX2NR1H4TRPV1 | |
| SCHEMBL4892768 | 0.82 | EPHX2 (0.66) | EPHX2NR1H4TRPV1NPC1RAB9A | |
| SCHEMBL4881016 | 0.82 | EPHX2 (0.53) | EPHX2NR1H4TRPV1 | |
| SCHEMBL4892103 | 0.81 | EPHX2 (0.52) | EPHX2NR1H4TRPV1 | |
| SCHEMBL4889666 | 0.79 | EPHX2 (0.75) | EPHX2NR1H4TRPV1 | |
| SCHEMBL3420620 | 0.75 | EPHX2 (0.65) | EPHX2NR1H4TRPV1NPC1RAB9A | |
| SCHEMBL785306 | 0.75 | NR1H4 (0.66) | EPHX2NR1H4TRPV1NPC1TSHR | |
| SCHEMBL4622881 | 0.74 | TRPV1 (0.56) | EPHX2NR1H4TRPV1 | |
| SCHEMBL4884181 | 0.74 | NR1H4 (0.49) | EPHX2NR1H4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071650-B2 | Vanilloid receptor modulators; analgesic, antiinflammatory and antiulcer effects; such as 1-(1H-indol-5-ylmethyl)-3-phenethylthiourea | PACIFIC CORPORATION (KR) | 2011-12-06 | — | — | US | disclosed |
| US-20080064687-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | SUH YOUNG G | 2008-03-13 | — | — | US | disclosed |
| EP-1303483-A4 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORP (KR) | 2004-11-03 | — | — | EP | disclosed |
| US-20030153596-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | PACIFIC CORPORATION (KR) | 2003-08-14 | — | — | US | disclosed |
| EP-1303483-A1 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORPORATION (KR) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002016318-A1 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORPORATION (KR) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153596-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | TAS2R40, TAS1R2, TAS2R45 | EPHX2 3810/4885NR1H4 690/4885TRPV1 18/4885 |
| US-20080064687-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | TRPV1, TRPA1, TAS2R5 | EPHX2 3840/4885NR1H4 640/4885TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.